
PathAI
Founded Year
2016Stage
Series C | AliveTotal Raised
$255MLast Raised
$165M | 4 yrs agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
-58 points in the past 30 days
About PathAI
PathAI provides artificial intelligence (AI)-powered research tools and services for pathology. It delivers the diagnosis and treatment of cancer by leveraging modern approaches in machine learning. The company offers biopharmacy lab services, clinical development services, drug and diagnostic development, and more. It was founded in 2016 and is based in Boston, Massachusetts.
Loading...
ESPs containing PathAI
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The endoscopy imaging analysis platforms market aims to improve the accuracy and standardization of endoscopic procedures through the use of artificial intelligence. This technology can potentially assist gastroenterologists in identifying precancerous lesions, detecting missed adenomas, and classifying and detecting early gastric cancers. Additionally, AI-driven algorithms and computer vision adv…
PathAI named as Challenger among 8 other companies, including Medtronic, Iterative Health, and Proscia.
Loading...
Research containing PathAI
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned PathAI in 6 CB Insights research briefs, most recently on Nov 27, 2024.
Expert Collections containing PathAI
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
PathAI is included in 4 Expert Collections, including Digital Health 50.
Digital Health 50
450 items
The most promising digital health startups transforming the healthcare industry
Digital Health
11,292 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Oncology Tech
463 items
This collection includes companies applying technology to cancer care, diagnosis, and treatment. Examples include vendors offering cancer detection and diagnosis, oncology clinical decision support, real-world data, and AI oncology drug discovery.
Artificial Intelligence
7,222 items
PathAI Patents
PathAI has filed 17 patents.
The 3 most popular patent topics include:
- machine learning
- clusters of differentiation
- classification algorithms

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
5/19/2023 | 8/27/2024 | Grant |
Application Date | 5/19/2023 |
---|---|
Grant Date | 8/27/2024 |
Title | |
Related Topics | |
Status | Grant |
Latest PathAI News
Feb 11, 2025
Bring AI-Powered Pathology Solutions to Brazil Largest Brazilian integrated healthcare network to implement the AISight® digital pathology image management system to enhance efficiency and advance clinical research February 11, 2025 09:00 ET PathAI BOSTON and SAO PAULO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- PathAI, a leader in digital and AI-powered pathology solutions, and Rede D’OR, the largest integrated healthcare network in Brazil, today announced a partnership that will bring PathAI’s cutting-edge technology to Rede D’Or’s network of hospitals and diagnostic centers, marking PathAI’s strategic entry into South America. Rede D’or will be the first major institution in Brazil to use digital pathology at scale. Rede D’Or will implement PathAI’s AISight®1 image management system across its pathology operations which support the national network of 78 hospitals. The platform integrates advanced AI algorithms, including PathAI’s AIM-Breast Biomarker panel supporting ER, PR, HER2, and Ki67 quantification, to support pathology workflows. Rede D’Or will also utilize PathAI’s tools for research purposes. “This collaboration is a testament to Rede D’Or’s dedication to delivering world-class healthcare to our patients,” said Fernando Soares, MD, Full Professor at the University of Sao Paulo and Head of the Department of Anatomic Pathology at Rede D’Or. “We are looking forward to integrating AISight into our pathology workflows to enhance precision and efficiency, particularly in oncology, while advancing our research capabilities amidst our continued expansion.” “This partnership demonstrates how leading healthcare institutions can successfully integrate digital and computational solutions to improve operational efficiency and advance research capabilities to deepen our understanding of diseases and refine treatment approaches,” said Andy Beck, MD, PhD, co-founder and CEO of PathAI. “Rede D’Or’s commitment to innovation in healthcare as a means to improve patient outcomes makes them the ideal partner for introducing our technology to the Latin American market.” This implementation supports Rede D’Or’s R$7.5 billion expansion plan, which aims to grow their network to over 125 facilities. For more information about PathAI, or AISight, please contact digital.dx@pathai.com or visit pathai.com . Footnotes AISight® is for Research Use Only in the US; AISight® Dx is CE-IVD marked in the EEA, UK, and Switzerland. About PathAI PathAI is a leading provider of integrated AI and digital pathology solutions dedicated to transforming workflow and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. For more information, please visit www.pathai.com . About Rede D’OR Rede D'Or Sao Luiz SA is a Brazil-based company engaged in the hospital's operation. The Company provides treatment in a number of areas, such as oncology, surgery, gynecology, cardiology, dietetics, neurology, dermatology, as well as pediatrics. Furthermore, the Company offers diagnostic services, scientific research and education partnerships, as well as learning programs for professionals, including doctors, nurses and psychologists. Its hospitals are located in the states of Rio de Janeiro, Sao Paulo, Pernambuco, Bahia, Sergipe, Maranhao, Parana, Ceara and Federal District, among others. Additionally, the Company operates a network of oncological clinics and analysis and imaging laboratories. About AISight AISight® is a cloud-native, intelligent enterprise workflow solution developed by PathAI to advance digital pathology practices. Serving as a central hub for case and image management, AISight integrates seamlessly with major laboratory information systems (LIS) and supports various scanners. Its browser-accessible, cloud-based architecture enables rapid activation and scalability without requiring additional infrastructure investments. Designed with pathologists in mind, AISight offers built-in image analysis and collaboration tools, providing an intuitive user experience. The platform also features an open AI environment, incorporating AI algorithms from PathAI and third-party partners to support multiple histopathology applications. Company Contact
PathAI Frequently Asked Questions (FAQ)
When was PathAI founded?
PathAI was founded in 2016.
Where is PathAI's headquarters?
PathAI's headquarters is located at 1325 Boylston Street, Boston.
What is PathAI's latest funding round?
PathAI's latest funding round is Series C.
How much did PathAI raise?
PathAI raised a total of $255M.
Who are the investors of PathAI?
Investors of PathAI include General Catalyst, Refactor Capital, General Atlantic, Bristol-Myers Squibb, 8VC and 15 more.
Who are PathAI's competitors?
Competitors of PathAI include Azra AI, Deciphex, Primaa, Perspectum, Aignostics and 7 more.
Loading...
Compare PathAI to Competitors

Paige specializes in the development of digital pathology platforms and generative AI applications within the healthcare sector. The company offers a cloud-based platform that enhances pathologists' workflow, increases diagnostic confidence and productivity, and provides AI-driven precision in cancer diagnosis. Paige's technology also aids pharmaceutical companies in evaluating treatment options and designing new biomarkers for drug development. It was founded in 2017 and is based in New York, New York.

Ibex specializes in AI-based cancer diagnostics within the healthcare technology sector. The company offers AI-powered diagnostic solutions that assist pathologists in providing accurate and efficient cancer diagnoses. Its solutions are developed using advanced algorithms and digital workflows to detect cancer with clinical-grade accuracy. It was founded in 2016 and is based in Tel Aviv, Israel.

Owkin is an AI biotechnology company that employs artificial intelligence to improve drug discovery and development in the biopharmaceutical sector. The company specializes in AI-based identification of new treatments, clinical trial optimization, and diagnostic tool creation, while ensuring patient privacy through federated learning techniques. Owkin serves the biopharma and academic research communities. It was founded in 2016 and is based in New York, New York.

AIRA Matrix provides Artificial Intelligence solutions for the Life Sciences sector, focusing on pathology laboratory workflows. The company offers products and services that aim to improve efficiency, diagnostic accuracy, and turnaround times in pathology, as well as provide diagnostic, prognostic, and predictive options for cancer care. AIRA Matrix serves hospitals, pharmaceutical companies, contract research organizations (CROs), and research labs globally. It was founded in 2011 and is based in Mumbai, India.

Proscia focuses on the development of software for the pathology sector. The company offers include a digital pathology platform and artificial intelligence (AI)-powered applications to facilitate routine pathology operations, research breakthroughs, and patient outcomes. Proscia primarily serves the life sciences and diagnostics sectors. It was founded in 2014 and is based in Philadelphia, Pennsylvania.
Aiosyn is a healthtech company focused on developing precision pathology software solutions for the healthcare sector. The company offers AI-powered algorithms that enhance digital pathology workflows and support clinical diagnostics, as well as tools for the identification of pathology-based biomarkers for drug development. Aiosyn primarily serves the healthcare industry, including pathology laboratories and biopharmaceutical companies. It was founded in 2021 and is based in Nijmegen, Netherlands.
Loading...